DOCSLIB.ORG

José Esparza, MD, Phd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
José Esparza, MD, Phd Nova Southeastern University NSUWorks Biology Faculty Articles Department of Biological Sciences 3-7-2014 Gene Discovery and Data Sharing in Genome Wide Association Analyses: Lessons Form AIDS Genetic Restriction Genes Stephen J. O'Brien St. Petersburg State University - Russia, [email protected] Anton Svitin St. Petersburg State University - Russia Sergey Malov St. Petersburg State University - Russia; St. Petersburg Electrotechnical University - Russia Nikolay Cherkasov St. Petersburg State University - Russia Pavel Dobrynin St. Petersburg State University - Russia See next page for additional authors Follow this and additional works at: https://nsuworks.nova.edu/cnso_bio_facarticles Part of the Genetics and Genomics Commons NSUWorks Citation O'Brien, Stephen J.; Anton Svitin; Sergey Malov; Nikolay Cherkasov; Pavel Dobrynin; Paul Geerts; Jennifer L. Troyer; Sher L. Hendrickson; Efe Sezgin; and Holli Hutcheson. 2014. "Gene Discovery and Data Sharing in Genome Wide Association Analyses: Lessons Form AIDS Genetic Restriction Genes." Journal of Acquired Immune Deficiency Syndromes 65, (Supplement 2): 59-59. https://nsuworks.nova.edu/cnso_bio_facarticles/722 This Article is brought to you for free and open access by the Department of Biological Sciences at NSUWorks. It has been accepted for inclusion in Biology Faculty Articles by an authorized administrator of NSUWorks. For more information, please contact [email protected]. Authors Stephen J. O'Brien, Anton Svitin, Sergey Malov, Nikolay Cherkasov, Pavel Dobrynin, Paul Geerts, Jennifer L. Troyer, Sher L. Hendrickson, Efe Sezgin, and Holli Hutcheson This article is available at NSUWorks: https://nsuworks.nova.edu/cnso_bio_facarticles/722 TH 1515TH ANNANNUALUAL INTERNATIONAL MEETING INTERNATIONAL Center forHIV/AIDSPreventionandTreatment the Institute ofHumanVirology SEPTEMBER 8–12,2013|MOSCOW Global Virus Network Global Virus IHV is an Institute at the at Institute an IHV is and in partnershipwith The Moscow L INTERNATIONAL MEETING UA Institute of Human Virology in partnership with the Global Virus Network and The Moscow ANNUAL ANN Contents H T Center for HIV/AIDS Prevention and Treatment TH 5 1 15 SEPTEMBER 8 –12, 2013 | MOSCOW CONTENTS EVENTS SCHEDULE SPEAKER SCHEDULE ABSTRACTS INDEX CONTENTS Click on any content title to link to that section. 03 Program Information and Acknowledgements* *as of press time 16 Events Schedule 19 Speaker Schedule 32 Abstracts Index 15th Annual International Meeting of the Institute of Human Virology 2 L INTERNATIONAL MEETING UA Institute of Human Virology in partnership with the Global Virus Network and The Moscow ANNUAL ANN Program Information and H T Center for HIV/AIDS Prevention and Treatment TH 5 1 15 SEPTEMBER 8 –12, 2013 | MOSCOW Acknowledgements CONTENTS EVENTS SCHEDULE SPEAKER SCHEDULE ABSTRACTS INDEX Welcome 15th Annual International Meeting of the Institute of Human Virology, in partnership with the Global Virus Network and the Moscow Center for HIV/AIDS Treatment and Prevention Dear Colleagues and Friends, preventive vaccines; we also address the roles for viruses in The Institute of Human Virology (IHV) at the University of human cancer, how they cause diseases and how they are Maryland School of Medicine, the Global Virus Network spread. Workshops provide practical lessons for managing (GVN), and the Moscow Center for HIV/AIDS Treatment co-morbidities of HIV/AIDS including hepatitis, cancer, and Prevention welcome you to the Institute’s 15th tuberculosis and diabetes. Truly, this meeting combines the Annual International Meeting. For only the second time best knowledge on diagnosis, treatment and prevention in IHV’s history, the meeting is convening outside of the of human viral diseases and will be an important event. Baltimore/Washington DC area. This year we gather in Moscow, a city obviously of deep historical significance We look forward to you joining us in beautiful Moscow and home to stunning architecture, cultural tradition, and to explore the most recent and important developments the Russian Federation Capitol. Further, uniquely this year, in HIV/AIDS research and other viral diseases and to the meeting will include presentations from members of acknowledge the progress and challenges in global the Global Virus Network, thereby broadening the scope health research. of the meeting. The IHV Annual Meeting has fostered international scientific cooperation since its inception. Sincerely, This year’s event recognizes both our commitment to the global fight against HIV/AIDS as well as a focus on several Robert C. Gallo, MD other human viral diseases, and the critical roles played Director and Professor by the scientists, physicians, and public health officials in Institute of Human Virology and the Russian Federation. We are pleased to join together Co-founder & Scientific Director of the for hosting this meeting and believe it will impact the Global Virus Network (GVN) future of research on viral diseases in our countries and Alexey Mazus, MD throughout our network of collaborating institutions. Head Moscow Center for HIV/AIDS Prevention This year’s open meeting is from Sunday, September 8 and Treatment through Wednesday, September 12. An outstanding program of Russian and international experts in medical virology will be presented in the Moscow City Meeting Sharon Hrynkow, PhD Hall. While our major focus continues to be in HIV/AIDS, President through the Global Virus Network, we will expand the Global Virus Network (GVN) scope to cover other important human viral diseases including hepatitis, measles, influenza, enterovirus, polio C. David Pauza, PhD and hemorrhagic fever. For each, we concentrate on the Associate Director and Professor latest developments in antiviral drug treatment or Institute of Human Virology 15th Annual International Meeting of the Institute of Human Virology 3 L INTERNATIONAL MEETING UA Institute of Human Virology in partnership with the Global Virus Network and The Moscow ANNUAL ANN Program Information and H T Center for HIV/AIDS Prevention and Treatment TH 5 1 15 SEPTEMBER 8 –12, 2013 | MOSCOW Acknowledgements CONTENTS EVENTS SCHEDULE SPEAKER SCHEDULE ABSTRACTS INDEX IHV is an Institute at the Mission Statement The Institute of Human Virology (IHV) is a world-class center of excellence focusing on chronic viral diseases and virally linked cancers. IHV is dedicated to biomedical research leading to improved treatment and prevention of these diseases. Our unique structure connects cohesive, multidisciplinary research and clinical programs so that new treatments are streamlined from discovery to patients. IHV is forging local and international programs for research and treatment of human disease. The IHV is also a Center of Excellence in the Global Virus Network (GVN), and this year’s meeting in Moscow will be immediately followed by a shorter GVN meeting. GVN President, Sharon Hrynkow, is the meeting coordinator with Professor Alexey Mazus. The mission of the Global Virus Network is to strengthen medical research and response to current viral causes of human disease and to prepare against new viral pandemic threats. The Moscow Center for HIV/AIDS Prevention and Treatment (AIDS Center) of the Moscow Health Department is the main unit of the city service providing HIV prevention and medical treatment services for Moscow citizens living with HIV/AIDS. 15th Annual International Meeting of the Institute of Human Virology 4 L INTERNATIONAL MEETING UA Institute of Human Virology in partnership with the Global Virus Network and The Moscow ANNUAL ANN Program Information and H T Center for HIV/AIDS Prevention and Treatment TH 5 1 15 SEPTEMBER 8 –12, 2013 | MOSCOW Acknowledgements CONTENTS EVENTS SCHEDULE SPEAKER SCHEDULE ABSTRACTS INDEX Institute of Human Virology (IHV) Board of Advisors Terry Lierman (Chair) Ernest F. Hollings Franco Nuschese Partner, Summit Global Ventures Medical University of Georgetown Entertainment Group Rockville, MD South Carolina Washington, DC Charleston, SC Peter Angelos Joseph Pagano Law Office of Peter G. Angelos Harry Huge, Esq. University of North Carolina at Baltimore, MD Harry Huge Law Firm, LLC Chapel Hill Charleston, SC Chapel Hill, NC Robert Charrow Greenberg-Traurig, LLP Mark Kaplan Peter Palese Washington, DC University of Michigan Mount Sinai School of Medicine Medical Center New York, NY Janet Langhart Cohen Ann Arbor, MI Langhart Communications James Pinkerton Chevy Chase, MD Sheilah A. Kast RATE Coalition WYPR Radio Arlington, VA Barbara J. Culliton College Park, MD Science Journalist and Policy The Honorable Stephanie Consultant The Honorable Nancy Kopp Rawlings-Blake Washington, DC State Treasurer Baltimore City Mayor Maryland State Government Baltimore, MD The Honorable Elijah Cummings Annapolis, MD US House of Representatives Edward “Chip” Robertson Baltimore, MD Reinhard Kurth Bartimus, Frickleton, Robertson & Ernst Schering Foundation Gorny, P.C. Mr. John Evans Berlin, Germany Jefferson City, MO Evans Telecommunications Ft. Lauderdale, FL Ray Lewis Kathleen Kennedy-Townsend Ray Lewis Foundation The Rock Creek Group The Honorable Arthur J. Gajarsa Baltimore, MD Baltimore, MD United States Court of Appeals for the Federal Circuit (Ret) Mr. Thomas Lynch Jeffrey Trammell Washington, DC Amarin Pharmaceutical, Ltd. Trammel and Company Dublin, Ireland Washington, DC Mr. Robert Gray Chairman, Gray and Company II HRH Princess Chulabhorn Lenny Wilkens Miami Beach, FL Mahidol National Basketball Association Hall Mahidol University of Fame Coach and Player Stewart Greenebaum
Load more

Recommended publications
  • Pan-Turkism and Geopolitics of China
    PAN-TURKISM AND GEOPOLITICS OF CHINA David Babayan* Introduction People’s Republic of China (PRC) is currently one of the most powerful and dy- namically developing countries of the world. The economic development of the country is particularly impressive, as explicitly reflected in key economic indices, such as Gross Domestic Product (GDP). For instance, China’s GDP in 2007 was $3.43 trillion1, and in 2010 it already amounted to $6 trillion2. The foreign trade volume of the country also grows at astronomical rates. In 1982 it was $38.6 bil- lion3, in 2002 – $620.8 billion, and in 2010 totaled to almost $3 trillion4. According to Sha Zukang, United Nations Under-Secretary-General for Economic and Social Affairs, China’s economic development is a sustained fast growth rare in modern world history5. Some experts even believe that while the first thirty years of China’s eco- nomic reforms program was about joining the world, the story of the next thirty years will be about how China reaches out and shapes the world6. Chinese analysts calculate the standing of nations by measuring “comprehensive national strength” of these nations7. This method relies on measuring four subsystems of a country’s national power: (1) material or hard power (natural resources, economy, science * Ph.D., History. 1 “China’s GDP grows 11.4 percent in 2007,” Xinhua, http://news.xinhuanet.com/english/2008-01/24/ content_7485388.htm, January 24, 2008. 2 Chen Yongrong, “China's economy expands faster in 2010, tightening fears grow”, Xinhua, http:// news.xinhuanet.com/english2010/china/2011-01/20/c_13699250.htm, January 20, 2011.
    [Show full text]
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • Clinical Scholars Visit Amish Research Clinic in Lancaster County, PA by Patrick Brunner, MD Dr
    Spring 2018 Center for Clinical and Translational Science e- e-NewsletterNewsletter Center News James Krueger and Marina Caskey, Representing the Nussenzweig Lab Team, Honored at Translational Science 2018 Meeting By Hospital Leadership which fulfill the translation research Dr. James Krueger received paradigm of going from bench to the Association for Clinical and bedside, have been recognized by this Translational Science (ACTS) most prestigious national recognition. Distinguished Investigator Award for his It is well deserved!” Upon receiving the groundbreaking research on psoriasis at award, Dr. Krueger noted, “This award the Translational Science 2018 meeting would not have been possible without attended by more than 1,100 people in the support of many others associated Washington, DC in April. His research with the Rockefeller CTSA enterprise: has led to a fundamental change in my lab members, the nursing staff, the paradigm for understanding the all other support departments and, pathophysiology of the disorder, and of course, hundreds of patients who this in turn has led to the development directly tested progressively better drugs of a series of novel medications that that are now used to so effectively treat precisely modulate the immune system psoriasis.” and dramatically improve the therapy of the disorder. Each year, Clinical Research Forum sponsors a competition to identify Dr. Caskey Receiving “Top Ten” Award from the “Top Ten” Clinical Research Drs. Harry Selker and Herb Pardes studies reported in the previous year. commented that “The study reflects the The competition is intense and so it very best in translational science: the is a true tribute to the novelty and careful analysis of patient phenotypes; importance of the study led by Dr.
    [Show full text]
  • Tibetan Studies in Russia: a Brief Historical Account
    Annuaire de l'École pratique des hautes études (EPHE), Section des sciences religieuses Résumé des conférences et travaux 126 | 2019 2017-2018 Religions tibétaines Tibetan studies in Russia: a brief historical account Alexander Zorin Electronic version URL: https://journals.openedition.org/asr/2498 DOI: 10.4000/asr.2498 ISSN: 1969-6329 Publisher Publications de l’École Pratique des Hautes Études Printed version Date of publication: 15 September 2019 Number of pages: 63-70 ISBN: 978-2909036-47-2 ISSN: 0183-7478 Electronic reference Alexander Zorin, “Tibetan studies in Russia: a brief historical account”, Annuaire de l'École pratique des hautes études (EPHE), Section des sciences religieuses [Online], 126 | 2019, Online since 19 September 2019, connection on 06 July 2021. URL: http://journals.openedition.org/asr/2498 ; DOI: https:// doi.org/10.4000/asr.2498 Tous droits réservés : EPHE Religions tibétaines Alexander ZORIN Directeur d’études invité Institut des Manuscrits Orientaux, Académie des Sciences de la Russie, Saint-Pétersbourg Tibetan studies in Russia: a brief historical account IBETOLOGY is one of the oldest branches of Oriental studies in Russia that used to Tbe closely connected with foreign and inner policy of the Russian State starting from the late 17th century. The neighborhood with various Mongolian politia and gradual spread of Russian sovereignty upon some of them caused the necessity of studying and using Tibetan along with Mongolian, Oirat, Buryat languages and also, from the 18th century, studying Tibetan Buddhism as the dominant religion of these people. Huge collections of Tibetan texts and Tibetan arts were gradually gathered in St. Petersburg and some other cities, and the initiator of this process was Peter the Great, the first Russian emperor.
    [Show full text]
  • Report on Global Surveillance of Epidemic-Prone Infectious Diseases, 2000
    Pan American Health Organization Regional Office of the World Health Organization PAHO/DPC/CD-V/243/03 Original: English Report: Workshop on Dengue Burden Studies (Washington, DC, 5-7 November 2002) Convened by The Pan American Health Organization The Rockefeller Foundation The Pediatric Dengue Vaccine Initiative Executive Summary Background Dengue fever (DF) and dengue hemorrhagic fever (DHF) are caused by the mosquito borne virus, dengue virus, of which there are four antigenically distinct serotypes. It is estimated that annually these viruses cause at least 20 million infections worldwide leading to some 24,000 deaths (WHO, http://www.who.int/health_topics/dengue/en/ ). The alarming rise in dengue hemorrhagic fever in the world today is illustrated most starkly by the chart below which represents data from the World Health Organization (WHO) showing the rise of DHF cases over the last four decades. Indeed the first two years of the new millennium has seen outbreak after outbreak of DHF not only in Southeast Asia where DHF has been seen for half a century, but also in many countries of South and Central America. REPORTED CASES OF DHF 600 ds 500 housan t 400 n d i e 300 200 r report e 100 numb 0 1955-1959 1960-1069 1970-1979 1980-1989 1990-1998 Source: WHO; adapted from http://www.who.int/health_topics/dengue/en/ While there is no doubt that severe dengue is spreading from countries in Southeast Asia to countries in the Pacific and in the Americas, there is also no doubt that many international efforts into the development of dengue vaccines have led to a number of promising vaccine candidates which may offer some solutions to the control of this disease.
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • 5Th Annual Short Course in Medical Virology Baltimore, MD August 5-11
    5th Annual Short Course in Medical Virology Baltimore, MD ǀ August 5-11, 2018 ǀ Program Locations: IHV ǀ Baltimore JH ǀ Baltimore NIH ǀ Bethesda Sunday, August 5 3:00 PM Hotel Check In 6:00-8:00 PM Short Course Opening Dinner at Diamond Tavern Monday, August 6 9:00-10:00 AM Shyam Kottilil, MD, PhD, Institute of Human Virology "Hepatitis C" 10:00-10:15 AM Coffee break 10:15- 11:15 AM Yutaka Tagaya, MD, PhD, Institute of Human Virology "Human T-cell leukemia virus-1, an exceptionally oncogenic retrovirus" 11:15-12:15 PM Robert Gallo, MD, Institute of Human Virology "Human Retroviruses: HTLV and HIV: an Overview” 12:15- 1:15 PM group picture & lunch 1:15-2:15 PM Jose Esparza, MD, PhD, Institute of Human Virology "Vaccines" 2:15-3:15 PM Alfredo Garzino-Demo, PhD, Institute of Human Virology "HIV Pathogenesis" 3:15-3:30 PM Coffee break 3:30- 4:30 PM Neil Constantine, PhD, Insitute of Human Virology "Laboratory diagnostics" Tuesday, August 7 8:15 AM Transportation to Johns Hopkins Bloomberg School of Public Health 9:00-10:00 AM Diane Griffin, PhD, MD, Johns Hopkins Bloomberg School of Public Health "Measles" 10:00-11:00 AM Ken Olson, PhD, Colorado State University "Arboviruses" 11:00-11:30 AM Break 11:30-12:30 AM Marcelo Jacobs-Lorena, PhD, Johns Hopkins Bloomberg School of Public Health Insectary Tour 12:30-1:30 PM Lunch 1:30-2:30 PM Transportation to IHV/ Coffee Break 2:30-4:30 PM GVN Short Course Partcipant's research presentations 4:30-5:30 PM Yuki Furuse, PhD, MD, Tohoku University, Japan New Emerging leader presentation: What can we do and what should we do during Ebola outbreak? Wednesday, August 8 9:00-10:00 AM Ab Osterhaus, DVM, PhD, University of Veterninary Medicine Hannover "One Health" 10:00-11:00 AM Stefan Sarafianos, PhD, Emory School of Medicine "Antiviral drug discovery" 11:30- 12:30 AM Robert Garry, PhD, Tulane University "Ebola and Lassa fever" 12:30-1:30 PM Lunch 1:30-2:30PM Konstantin Chumakov, FDA “Polio and other Enteroviruses” 2:30-3:30 PM Richard H.
    [Show full text]
  • Filoloji V2.Pdf
    İmtiyaz Sahibi / Publisher • Yaşar Hız Genel Yayın Yönetmeniİmtiyaz Sahibi / Editor / Publisher in Chief • Yaşar• Eda AltunelHız Kapak &Genel İç Tasarım Yayın / YönetmeniCover & Interior / Editor Design in Chief • Gece • Eda Kitaplığı Altunel Kapak Editör& İç Tasarım / Edıtor / Cover• Doç. &Dr. Interior Yılmaz DKURT esign • Gece Kitaplığı BirinciEditör Basım // EdıtorFirst Edition • Prof. • Dr. © Aralık Serdar 2020 Öztürk ISBN • 978-625-7702-89-8 Birinci Basım / First Edition • © Aralık 2020 ISBN • 978-625-7319-31-7 © copyright Bu kitabın yayın hakkı Gece Kitaplığı’na aittir. Kaynak gösterilmeden alıntı yapılamaz, izin almadan hiçbir yolla çoğaltılamaz. The right to publish this book belongs to Gece Kitaplığı. Citation can not be shown without the source, reproduced in any way without permission. Gece Kitaplığı / Gece Publishing Türkiye Adres / Turkey Address: Kızılay Mah. Fevzi Çakmak 1. Sokak Ümit Apt. No: 22/A Çankaya / Ankara / TR Telefon / Phone: +90 312 384 80 40 web: www.gecekitapligi.com e-mail: [email protected] Baskı & Cilt / Printing & Volume Sertifika / Certificate No: 47083 Filoloji Alanında Teori ve Araştırmalar II EDİTÖR Doç. Dr. Yılmaz KURT İÇİNDEKİLER BÖLÜM 1 GOLAN TÜRKMENLERİNDE YIR SÖYLEME GELENEĞİ Mehmet EROL ......................................................................................1 BÖLÜM 2 ÇORY YAZITI’NDAN MİLLET MEKTEPLERİNE TÜRKÇE METİN YAZIMINDA KULLANILAN YAZI SİSTEMLERİ Rabia Şenay ŞIŞMAN ........................................................................21 BÖLÜM 3 AHMED KUDDÛSÎ DİVANI’NDA
    [Show full text]
  • José Esparza MD, Phd - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
    Vaccination: lost opportunities José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. - Formerly at the World Health Organization (Geneva, Switzerland) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). Outline • The public health value of vaccination • Different types of vaccine hesitancy • Some historical examples of vaccine introduction and impact • The case of dengue vaccines • Conclusions Ten Great Public Health Achievements of the 20th Century (in the US) 1. Vaccines 2. Motor vehicle safety 3. Workplace safety 4. Control of infectious diseases 5. Decline in deaths from hearth disease and stroke 6. Safer and healthier foods 7. Healthier mothers and babies 8. Family planning 9. Fluoridation of drinking water 10. Tobacco as a health hazard www.cdc.gov/about/history/tengpha.htm The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) Vaccine-preventable diseases, by year of vaccine development or licensure. United States,1798-1998. Vaccine Introduction Vaccine Introduction Smallpox 1798 Rubella 1969 Rabies 1885 Antrax 1970 Typhoid 1896 Meningitis 1975 Cholera 1896 Pneumonia 1977 Plague 1897 Adenovirus 1980 Diphtheria 1923 Hepatitis B 1981 Pertussis 1926 H. Influenza B 1985 Tetanus 1927 Japanese encephalitis 1992 Tuberculosis 1927 Hepatitis A 1995
    [Show full text]
  • Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments
    Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments AVAC gratefully acknowledges many friends and colleagues in government, industry, academia and the advocacy community from all over the world for their expertise, guidance and advice as we researched and prepared this Report. AVAC Report 2009 was written and edited by AVAC staff, consultants and board members, and coordinated by Emily Bass. We also want to especially thank Sarah Alexander, Dan Barouch, Linda-Gail Bekker, Seth Berkley, Alan Bernstein, Susan Buchbinder, Gabriela Calazans, Ward Cates, Mark Connors, Larry Corey, Paul de Bakker, Guy de Bruyn, Kevin De Cock, Carl Dieffenbach, Kim Dickson, Jose Esparza, Tim Farley, Patricia Fast, Mark Feinberg, Jorge Flores, David Goldstein, Gregg Gonsalves, Glenda Gray, Yasmin Halima, Cate Hankins, Mark Harrington, Barton Haynes, Sharon Hillier, Peggy Johnston, Richard Klausner, Wayne Koff, Katharine Kripke, Jim Kublin, Dave Levin, Udom Likhitwonnawut, Margaret Liu, Ying Ru Lo, Donna Lomangino, Siobhan Malone, Kay Marshall, Betsy Martin, John Mascola, Bonnie Mathieson, Margaret McCluskey, Elizabeth McGrory, James McIntyre, Natasha Mileshina, Lynn Morris, Kevin O’Reilly, Saladin Osmanov, Myra Ozaeta, Giuseppe Pantaleo, Lynn Paxton, Louis Picker, Frances Priddy, Helen Rees, Robert Reinhard, Supachai Rerks-Ngarm, Mike Robertson, Candace Rosen, Nina Russell, Jerry Sadoff, Jeff Safrit, Allan Schultz, Robin Shattock, Guido Silvestri, Joan Tallada, Jim Tartaglia, Gerald Voss, Sabrina Welsh and Carolyn Williamson. AVAC is dedicated
    [Show full text]
  • Vol. 23, No. 2, 2019
    The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG | VOLUME 23, ISSUE 2 | DECEMBER 2019 A new viral vaccine The history of A new efficacy trial of vector has broad vaccination: adapting the mosaic HIV vaccine potential to the times candidate FROM THE EDITOR “It was the best of times, it was the worst of times…” from Janssen Vaccines & Prevention, part of the Jans- So begins Charles Dickens’s famous historical novel A sen Pharmaceutical Companies of Johnson & Johnson, Tale of Two Cities, published in 1859. Dickens was together with a consortium of public partners, began describing the years leading up to the French their second, and largest, efficacy study (named Revolution, yet it is an oddly apt description of the Mosaico) of Janssen’s mosaic-based HIV vaccine candi- current state of the vaccine field. date (see page 16). This October, the first Ebola vaccine was approved by Based on this, one might think it was the best of times. the European Medicines Agency. This is by all accounts But amidst all this progress, global cases of measles are an important milestone in battling outbreaks of a lethal on the rise, a disease for which a highly effective vaccine infectious disease that most often affects people in devel- has been available for more than 50 years. Last year oping countries. This vaccine, known as Ervebo, was more than 140,000 people worldwide died of measles, rapidly developed in 2014 during the deadliest outbreak most of them children under five years old, and 100 mil- of Ebola in history. It is estimated to be 97.5% effective.
    [Show full text]
  • 2008 Annual Progress Report
    International AIDS Vaccine Initiative 2008 Annual Progress Report avi IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. OFFICES New York Headquarters 110 William Street, Floor 27 New York, N..Y. 10038-3901 U.S.A. Tel: +1 212 847 1111 Fax: +1 212 847 1112 East Africa Postal address: P.O. Box 340 KNH Nairobi, Kenya 00202 Tel: +254 20 445 3596/7 Fax: + 254 20 445 3598 Europe Herengracht 208 1016 BS Amsterdam The Netherlands Tel: +31 20 521 0030 Fax: +31 20 521 0039 India D-64, Second Floor, Defence Colony New Delhi, 110 024, India Tel: +91 11 24652668 Fax: +91 11 24646464 Southern Africa Ground Floor, Block 6, Albury Park Corner Albury Road & Jan Smuts Avenue Dunkeld West 2196 Johannesburg, South Africa Tel: +27 11 325 4737 Fax: +27 11 759 6210 www.iavi.org ) [email protected] Copyright © 2009 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc. This report is available online at http://www.iavi.org. Evolution The new AIDS Vaccine The new IAVI Neutralizing A fully operational Design and Development Antibody Center at The Innovation Fund to promote Laboratory Scripps Research Institute cutting-edge science JULIANA THOMAS PHOTOGRAPHY Commitment Global Clinical Community network of trial center outreach and partnerships support social science VANESSA VICK Promise Build scientific and Sustain local, Ensure access to human capacity in national and global vaccines where the developing world focus on ending AIDS they’re needed most VANESSA VICK Message from the President Since we were founded in 1996, the International AIDS Vaccine Initiative has undergone constant change as we have pursued our mission of ensuring the development of an AIDS vaccine for the world.
    [Show full text]